The AI CEO with Seema Alexander

The episode contains substantive insights about AI in pharma regulation, clinical trials, and drug development timelines, with concrete examples like protein folding reducing from years to days. However, significant portions involve repetition of earlier points, tangential personal anecdotes (cousin's blood test, kids watching pharma ads), and filler questions that don't advance the discussion. The guest delivers useful frameworks around disciplined innovation and governance, but the pacing dilutes impact.

“In the past, understanding how proteins fold, it used to take years of lab research to do it. Now we can do it in days, right. And perhaps in months.”

“I look at it as disciplined innovation. So I think a lot of times you think of safety as your brake and innovation as your gas pedal. But I think in this particular instant you need to build innovation right from the get go.”

The guest rehashes standard pharma-AI talking points: efficiency gains, precision medicine, omnichannel engagement, and regulatory lag. While the framing around 'disciplined innovation' and digital medical liaisons is competent, these are not novel takes - they reflect mainstream pharma strategy already documented in industry reports. The host's tangents about direct-to-consumer AI and OpenAI Health, while timely, generate reactive commentary rather than fresh thinking.

“healthcare is a very heavily regulated industry, you want to take safety and innovation together”

“I think improving patient outcomes, that's a higher bar.”

Kausar Riaz Ahmed brings credible credentials: 9 years at FDA in regulatory affairs, now leading generative AI for medical engagement at Pfizer, and involved in venture strategy. She has hands-on experience navigating both regulatory and commercial AI implementation at scale. However, she functions primarily as a thoughtful executor/explainer rather than a pioneer breaking new ground, and some discussion veers into generalist territory beyond her core expertise.

“I spent about nine years at The FDA regulating products”

“director of Generative AI for Medical engagement at Pfizer”

The episode includes some valuable specifics: phase 3 trials can exceed $500M and run 4-5 years, protein folding reduction from years to days/months, AI reducing R&D time by 30-40%, doctors correct 80% vs AI 85-90%. However, many claims lack supporting numbers or sources (e.g., 'over 40 million people using ChatGPT for health,' '100 doctors information already in here' from startups). General regulatory references to HIPAA, FDA, omnichannel strategy lack concrete examples of actual implementations.

“phase three clinical trial could sometimes go over 500 million. So I think phase three clinical trial”

“if AI can be correct 90% of the time, 85% of the time, then I think, in my opinion, in my honest assessment, I think that should be enough”

The host asks follow-up questions and attempts to probe deeper (e.g., 'How do you verify that there is a digital twin medical liaison AI company that is doing it right?'), but often pivots away before extracting full depth. Many questions lead into personal anecdotes or tangents rather than pressing the guest on contradictions or unexplored implications. The host telegraphs agreement frequently ('I love it') and rarely challenges assumptions. The conversation feels more like mutual agreement-building than rigorous inquiry.

“So when I say board, I'm saying you are part of that committee. You are helping initiate a lot of the conversations”

“But here's the question to you, because doctors aren't always right. Right. Even Data centers are 99.9% uptime. Right. There's always a 1 or 0.1% or something. Right.”